凯姆费里德通过向HIF-1信号通路来抑制骨关节炎的进展

Xianjie Wei^1,2, Hesuyuan Huang¹, Ping Yuan³

¹Orthopedics Department, Peking University Shougang Hospital, Beijing 100144, China.

Chinese medical journal

|September 17, 2025

概括

凯姆费里德 (KA) 通过减少炎症和软骨损伤,有效治疗骨关节炎 (OA). 这项研究揭示了KA针对低氧诱导因子-1 (HIF-1) 途径,为OA提供了一种新的治疗方法.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

骨关节炎 (OA) 是一种广泛的退行性关节疾病,导致疼痛和残疾,需要新的治疗方法.
凯姆费里德 (KA) 是一种具有已知的抗炎作用的黄类药物,对OA具有潜在的治疗价值.
在OA进展中KA的精确机制需要进一步研究.

研究的目的:

在骨关节炎 (OA) 模型中研究kaempferide (KA) 的治疗潜力.
通过转录组测序,阐明KA在OA中的作用的基础分子机制.

主要方法:

建立了使用IL-1β刺激SW1353细胞的体外OA模型和体内帕帕因诱导的OA大鼠模型.
通过qRT-PCR,ELISA,西部斑点,组织学分析和行为测试来评估KA的抗炎和冠状腺保护作用.
采用转录组测序来识别差异表达基因 (DEG) 和受KA.影响的信号通路.

主要成果:

在实验室中,KA治疗改善了状细胞的活力,减少了炎症标志物和软骨降解.
在体内研究表明,KA减轻了OA大鼠的软骨损伤和改善了OA大鼠的步态.
转录组分析确定了缺氧诱导因子-1 (HIF-1) 途径作为关键目标,KA调节HIF-1α和IFN-γ的表达.

结论:

凯姆费里德 (KA) 在抑制骨关节炎 (OA) 进展方面显示出显著的治疗潜力.
卡通过准HIF-1信号通路来发挥其作用,从而减少炎症和软骨退化.
这些发现凸显了KA作为新型OA疗法的有前途的候选人.

关键词:

在HIF-1信号通道中,在IL-1β的研究中,IL-1β被认为是IL-1β.卡姆菲里德 (Kaempferide) 是一种类动物.通过NF-κB信号通路传递信号.骨关节炎是一种骨关节炎.

相关概念视频

01:24

Regulation of Angiogenesis and Blood Supply

3.3K

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

3.3K

01:16

TGF - β Signaling Pathway

10.5K

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

10.5K

01:20

The JAK-STAT Signaling Pathway

12.1K

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

12.1K

01:07

MAPK Signaling Cascades

7.9K

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

7.9K

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

942

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

942

01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

567

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

567